C10640: Methylation Based Biomarkers for Ovarian Cancer Value Proposition: ADVANTAGES:
• Biomarkers for early detection/diagnosis of ovarian cancer
• Predictive biomarkers for risk of developing ovarian cancer
• Biomarkers for the prediction of therapy response
• Biomarkers to determine preventative interventions
• Biomarkers for prognostic outcome
Technical Details:
Ovarian cancer is the eighth most common cancer among women with ~ 22,000 new cases in the US each year, accounting for ~3% of all cancers in women. Ovarian cancer, also known as the silent killer is generally asymptomatic in its early stages. Most patients who are diagnosed are at advanced stages of the disease, making early detection of ovarian cancer a major unmet need.
Understanding the epigenetic changes that lead to cancer progression will help unravel key biologic processes that lead to cancer formation. Moreover, understanding the timing of these epigenetic changes will allow us to identify new molecular markers that will help determine risk, offer preventative approaches, detect early, predict responses to therapies, and help to determine the overall outcome. JHU scientists have identified methods for detecting, diagnosing, or evaluating ovarian cancer by detecting methylation changes as well as identifying a novel panel of ovarian cancer biomarkers.
Looking for Partners:
The commercial applications for this invention include markers for the identification of ovarian cancer, markers for the identification of appropriate preventative interventions, and markers to predict the outcome of a particular therapy for ovarian cancer.
